Jazz Pharmaceuticals, Inc. (JAZZ)
Q2 2012 Earnings Call
August 7, 2012 4:30 pm ET
Ami Knoefler – Executive Director, Investor Relations and Corporate Communications
Bruce C. Cozadd – Chairman and Chief Executive Officer
Kathryn E. Falberg – Executive Vice President and Chief Financial Officer
Russell J. Cox – Executive Vice President and Chief Commercial Officer
Jeffrey K. Tobias – Executive Vice President, Research and Development and Chief Medical Officer
Douglas D. Tsao – Barclays Capital, Inc.
David Amsellem – Piper Jaffray
Chris Holterhoff – Oppenheimer & Co. Inc.
Michael Faerm – Credit Suisse Securities
William Tanner – Lazard Capital Markets
Michael W. Schmidt – Leerink Swann LLC
Good afternoon, ladies and gentlemen, and welcome to the Jazz Pharmaceuticals Second Quarter 2012 Conference Call. Following an introduction from the company, we will open the call to questions.
I will now to turn the call over to Ms. Ami Knoefler, Head of Investor Relations and Corporate Communications at Jazz Pharmaceuticals. Ma’am you may proceed.
Welcome to the Jazz Pharmaceuticals second quarter 2012 financial results conference call. We reported financial results in a press release issued earlier today. The release is available in the News & Events section on our company website. Among other things, the press release includes a reconciliation of GAAP net income to adjusted net income for Jazz Pharmaceuticals plc, along with the related per share amount.
With me for today's call are Bruce Cozadd, Chairman and CEO; Kate Falberg, CFO; Russ Cox, Chief Commercial Officer; and Jeff Tobias, Head of R&D and Chief Medical Officer. Also joining us is William Craumer, our new Director of Investor Relations. Following some prepared comments, we'll open the call for your questions.